BTIG analyst David Larsen raised the firm’s price target on LifeStance (LFST) to $11 from $10 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 for Healthcare IT and Digital Health names. The firm is positive on the stock being among proven operators that have been performing consistently well, through many different cycles, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- LifeStance Health Group: Operational Efficiency Initiatives Undervalued, Supporting Buy Rating and Upside Potential
- LifeStance price target raised to $8.50 from $6.50 at KeyBanc
- LifeStance price target raised to $9 from $8 at Canaccord
- LifeStance price target raised to $10 from $9 at BTIG
- LifeStance initiated with an Overweight at Barclays